Cardiac Valve Market Poised for Remarkable US$ 18.72 Billion Valuation by 2030

Cardiac Valve Market Snapshot

“The Cardiac Valve Market to grow from USD 8.4 Billion in 2023 to USD 18.72 Billion by 2030, at a CAGR of 6.3%.”

A cardiac valve is a one-way valve that controls blood flow through the heart's chambers, typically consisting of four valves. These valves open or close based on blood pressure differentials on each side of the heart.

The cardiac valve is a crucial part of the cardiovascular system, regulating blood flow within the heart chambers. Its specialized aperture is a precise mechanism for accurate blood flow management.

If the native valve is damaged, a cardiac valve replacement operation is necessary to restore the heart's normal function. The implanted device regulates blood circulation's direction and pressure.

The mammalian heart consists of four valves: the mitral valve in the left heart and the tricuspid valve in the right heart, which divide the upper atria from the lower ventricles, and the aortic valve at the aorta and the pulmonary valve at the pulmonary artery.

The endocardium lines the heart's chambers and valves, which divide the ventricles from blood vessels or atria. Heart valves are located in fibrous rings of the cardiac skeleton and have leaflets, or cusps, that open to allow blood flow and close to seal and prevent backflow.

The mitral valve has only two cusps, with nodules on the cusp tips to tighten the seal.

>>>Download Sample Report Now:https://marketreportservice.com/request-sample/cardiac-valve-market-54697 

Key Insights

• North America holds the highest position as the largest shareholder in the global market.
• Cardiac wall repair is the primary treatment segment.
• The type segment is primarily controlled by the mitral valve.
• The valve position segment is primarily dominated by tissue/bioprosthetic valves.
• Hospitals and clinics are primarily responsible for serving the end-user segment.

Segment Analysis

Segment by Treatment

Heart valve disease is a condition that occurs when any of the four heart valves, which maintain the proper direction of blood flow through the heart, is not functioning properly.

Heart valve surgery involves a surgeon replacing or repairing damaged or sick valves, with open or minimally invasive options available. The type of surgery depends on age, health, and the severity of heart valve disease.

Cardiac Valve Repair or Replacement Surgery

The heart, composed of muscle tissue, has four pumping chambers, divided into ventricles and atria, which facilitate blood flow through valves between each chamber, facilitating the movement of blood.

• The tricuspid valve is situated between the right atrium and the right ventricle.
• The pulmonary valve is situated between the right ventricle and the pulmonary artery.
• The mitral valve is situated between the left atrium and the left ventricle.
• The aortic valve is situated between the left ventricle and the aorta.

The risks associated with heart valve repair or replacement surgery include:

• Bleeding during or after surgery.
• Blood clots can lead to heart attack, stroke, or lung issues.
• Infection
• Breathing issues
• The repaired or replaced valve doesn't work correctly

Growth Drivers

The market's growth is driven by the rising prevalence of heart valve disease and the increasing number of innovative, enhanced cardiac valves gaining regulatory approval, which is a key driving factor.

The cardiac valve market is experiencing rapid growth due to increasing prevalence of heart valve problems and cardiovascular disorders. Technological advancements and congenital cardiac illness are driving the market. People's increasing reliance on external food sources and neglect of their health are also driving the demand for heart valve products. The market is expected to strengthen with multiple acquisitions during the forecast period.

The cardiac valve market is expected to grow between 2023 and 2030 due to factors such as the increasing number of people with cardiovascular diseases, the aging population, the increasing use of heart valves for blood pressure control, and the increasing investment in technologically innovative products. This growth is also influenced by changing lifestyles.

Market Restraints

The market for medical products is hindered by stringent government regulations, affecting the availability of qualified surgeons and putting patients' health at risk.

The market faces difficulties in finding quick solutions, high costs of surgical procedures and equipment, and reimbursement concerns, which hinder market expansion and increase market value. These issues pose significant financial risks for the industry.

The market for cardiac valves is predicted to be limited by the high cost of these devices and the rising infection rates linked to their use.

Opportunity

The medical field is expected to experience rapid growth due to increased awareness of diagnosis and treatment options, government regulations, and increased healthcare spending in developing nations. The market is expected to develop in the coming years due to the introduction of new products, minimally invasive procedures, and the introduction of new technology, resulting in a wealth of potential market opportunities.

Competitive Landscape of the Cardiac Valve Market Analysis

• Medtronic
• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• LivaNova PLC
• Abbott
• CryoLife, Inc
• On-X Life Technologies, Inc.
• Colibri Heart Valve
• JenaValve Technology, Inc.
• TTK HealthCare

New Developments in Cardiac Valve Market

FEB 22, 2023- Medtronic relaunches first-of-its-kind transcatheter pulmonary valve replacement system for congenital heart disease

Medtronic announced the relaunch of its Harmony™ Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).

Congenital heart disease (CHD) is the most common type of birth defect in the United States, affecting an estimated 40,000 infants each year. and 1.6 million who live with the disease.

Approximately one in five patients born with CHD have structural malformations that disrupt the connection between the heart and the lungs, or the RVOT. The current standard of care is open-heart surgery or other interventions early in life to address these malformations.

For the 80% of CHD patients who require a native or surgically repaired RVOT at birth, many will need a pulmonary valve replacement later in life, which often requires another open-heart surgery.

May 7, 2023- Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety And Efficacy Outcomes In Seven Year Data

Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative RESILIA tissue.

The data, which represent the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were presented today at the 103rd annual meeting of the American Association for Thoracic Surgery.

Regional Analysis of Global Cardiac Valve Industry

North America holds the largest market share in the global cardiac valve market, with 43.5% in 2022. This dominance is attributed to advancements in medical knowledge, innovative heart valve products, and established laws for production and maintenance.

These factors have contributed to the overall success of the North America market, demonstrating its potential for significant growth in the future.

The increasing prevalence of lifestyle issues like obesity and diabetes has significantly accelerated the market's growth in the North American region.

The US market holds a dominant position in the industry, while the Canadian market has experienced the fastest growth rate, indicating a promising outlook for further market expansion. The current situation warrants careful consideration.

In 2022, the European Cardiac Valve market grew significantly due to heart valve issues, technological advancements, and robust healthcare systems. The UK market experienced the highest growth rate in the European region, while the German market held the largest market share.

The Asia Pacific cardiac valve market is expected to grow significantly from 2023 to 2030 due to the increasing prevalence of heart conditions like aortic stenosis, expansion of healthcare facilities in China and India, and industry players seeking new markets. 1 in 8 elderly Australians are likely to have aortic stenosis, with severe aortic stenosis affecting 97,000 over 55.

China holds the largest market share in the Asia-Pacific region, while India has the fastest-growing market.

Segments Covered in the Cardiac Valve Market Report

Segment by Treatment

• Cardiac Valve Repair
• Cardiac Valve Replacement

Segment by Position

• Mitral Valve
• Aortic Valve
• Other Position

Segment by Type

• Trans-Catheter Heart Valve
• Tissue Heart Valve
• Mechanical Heart Valve
• Others

Segment by End-user

• Cardiac Research Institute
• Hospital and Clinics
• Speciality centers
• Others

Market by Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Rest of the World
• Middle East
• Africa
• Latin America

Frequently Asked Questions

What are some applications of Cardiac Valve?

Valves are flaps on the lower chambers of the heart that prevent backward blood flow. They act as one-way inlets and outlets, ensuring that blood flows in and out of the ventricles.

What is the expected growth rate of the Cardiac Valve market over the next 7 years?

Cardiac Valve Market is estimated to increase at a CAGR 6.3% from $ 8.4 Billion in 2023 to $ 18.72 Billion by 2030.

Who are the major players in the Cardiac Valve market and what is their market share?

Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, LivaNova PLC, Abbott, CryoLife, Inc, On-X Life Technologies, Inc., Colibri Heart Valve, JenaValve Technology, Inc., and TTK HealthCare, are prominent players operating and dominating in the market.

Who are the top 3 Cardiac Valve Market Key Vendors?

Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, are key players in the Cardiac Valve market.

Which geographical areas dominate the worldwide market for Cardiac Valve?

North America region are emerging as the top regional markets for Cardiac Valve solutions.